D-CIK + gemcitabine + cisplatin

This is a **combination therapy** comprising three modalities: dendritic cell-cytokine-induced killer cells (D-CIK, a form of adoptive cell immunotherapy), **gemcitabine** (a nucleoside analog antineoplastic agent), and **cisplatin** (a platinum-based chemotherapy agent). D-CIK cells are expanded from a patient’s own mononuclear cells ex vivo by stimulation with specific cytokines and are reinfused to exert non-MHC-restricted cytotoxicity against tumor cells, enhance immune responses, and regulate cytokine profiles. Gemcitabine inhibits DNA synthesis in dividing cells, while cisplatin induces DNA crosslinking and apoptosis. This combination aims to improve immune function, quality of life, and survival in cancer patients—especially those with locally advanced gastric cancer and colorectal cancer following surgery or standard chemotherapy, showing increased T-cell and NK-cell counts and improved immune parameters, with manageable toxicity[1][3][7].

Other names

DC-CIK + gemcitabine + cisplatin